Literature DB >> 26744538

Pathophysiology of tumour-induced microangiopathic haemolytic anaemia.

Pavani Chalasani1, Jennifer M Segar2, Marilyn Marron1, Alison Stopeck3.   

Abstract

Cancer-associated microangiopathic haemolytic anaemia (CA-MAHA) is a syndrome characterised by Coombs-negative haemolytic anaemia and thrombocytopenia. It is primarily seen in advanced solid tumours and is distinct from thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome. Diagnosis is often delayed and patients have a high mortality. We present the case of CA-MAHA in a patient with metastatic breast cancer treated successfully with early initiation of chemotherapy. In addition, we report longitudinal laboratory evaluation of circulating tumour cells and microparticles and suggest a hypothesis for the mechanism behind CA-MAHA. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26744538      PMCID： PMC4716353          DOI： 10.1136/bcr-2015-213521

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  8 in total

1.  Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker.

Authors:  Sayyed Farshid Moussavi-Harami; Kari B Wisinski; David J Beebe
Journal:  J Patient Cent Res Rev       Date:  2014

Review 2.  Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases.

Authors:  Klaus Lechner; Hanna Lena Obermeier
Journal:  Medicine (Baltimore)       Date:  2012-07       Impact factor: 1.889

3.  The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinomas.

Authors:  G F Pineo; E Regoeczi; M W Hatton; M C Brain
Journal:  J Lab Clin Med       Date:  1973-08

4.  Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma.

Authors:  M C Brain; J G Azzopardi; L R Baker; G F Pineo; P D Roberts; J V Dacie
Journal:  Br J Haematol       Date:  1970-02       Impact factor: 6.998

5.  Microangiopathic haemolytic anaemia with advanced breast carcinoma: improvement with chemotherapy.

Authors:  C J Rodenburg; M A Nooy; E Briët
Journal:  Neth J Med       Date:  1985       Impact factor: 1.422

6.  Breast Cancer-Associated Thrombotic Microangiopathy.

Authors:  Anne C Regierer; Dagmar Kuehnhardt; Carsten-Oliver Schulz; Bernd Flath; Christian F Jehn; Christian W Scholz; Kurt Possinger; Jan Eucker
Journal:  Breast Care (Basel)       Date:  2011-12-15       Impact factor: 2.860

7.  Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy.

Authors:  J E Cantrell; T M Phillips; P S Schein
Journal:  J Clin Oncol       Date:  1985-05       Impact factor: 44.544

8.  Cancer awareness in atypical thrombotic microangiopathies.

Authors:  Lucie Oberic; Marc Buffet; Mickael Schwarzinger; Agnès Veyradier; Karine Clabault; Sandrine Malot; Nicolas Schleinitz; Dominique Valla; Lionel Galicier; Leila Bengrine-Lefèvre; Norbert-Claude Gorin; Paul Coppo
Journal:  Oncologist       Date:  2009-08-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.